|
Other anticoagulants
Citations 1-10 of 91 total displayed.
|
Most recent content
(2 Nov 2009):
|
- Articles
Major Bleeding, Mortality, and Efficacy of Fondaparinux in Venous Thromboembolism Prevention Trials
- John W. Eikelboom, Daniel J. Quinlan, and Martin O'Donnell
Circulation published November 2, 2009, doi:10.1161/CIRCULATIONAHA.109.872630
[Abstract]
|
Past content
(since Jan 2001):
|
- Editorials
New Therapies for Stroke Prevention in Atrial Fibrillation: The Long Road to Enhanced Efficacy
- Jane E. Freedman and Bernard J. Gersh
Circulation 2009;120:1024-1026; published online before print as doi:10.1161/CIRCULATIONAHA.109.893362
[Full text]
- Arrhythmia/Electrophysiology
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
- David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation 2009;120:1029-1035; published online before print as doi:10.1161/CIRCULATIONAHA.109.856120
[Abstract]
[Full text]
- Articles
New Therapies for Stroke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy
- Jane E. Freedman and Bernard J. Gersh
Circulation published September 9, 2009, doi:10.1161/CIRCULATIONAHA.109.893362
[Abstract]
- Articles
New Therapies for Stoke Prevention in Atrial Fibrillation. The Long Road to Enhanced Efficacy
- Jane E. Freedman and Bernard J. Gersh
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.893362
[Abstract]
- Articles
The First Evaluation of a Novel Vitamin K Antagonist, Tecarfarin (ATI-5923), in Patients With Atrial Fibrillation
- David J. Ellis, Mohammed Haris Usman, Peter G. Milner, Daniel M. Canafax, and Michael D. Ezekowitz
Circulation published September 8, 2009, doi:10.1161/CIRCULATIONAHA.109.856120
[Abstract]
- Coronary Heart Disease
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
- APPRAISE Steering Committee and Investigators
Circulation 2009;119:2877-2885; published online before print as doi:10.1161/CIRCULATIONAHA.108.832139
[Abstract]
[Full text]
- Articles
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome. Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial
- APPRAISE Steering Committee and Investigators
Circulation published May 26, 2009, doi:10.1161/CIRCULATIONAHA.108.832139
[Abstract]
- Editorials
Adverse Prognostic Significance of Thrombocytopenia in Acute Coronary Syndrome: Can Anything Be Done About It?
- Theodore E. Warkentin and Mark A. Crowther
Circulation 2009;119:2420-2422, doi:10.1161/CIRCULATIONAHA.109.858316
[Full text]
- Editorials
Stopping the Hemorrhage: A New Baseline Bleeding Score Brings Us a Step Closer for Patients With Non–ST-Elevation Myocardial Infarction
- Jeffrey L. Anderson
Circulation 2009;119:1846-1849, doi:10.1161/CIRCULATIONAHA.109.854281
[Full text]
|
|
